Pall Enters Laboratory Water Market With New Cascada Lab Water System

Food and Healthcare Press Releases Tuesday March 1, 2005 16:46
EAST HILLS, N.Y.--(BUSINESS WIRE)--Feb. 28, 2005--

Purified water is an essential and growing requirement of research and diagnostic laboratories. Water quality can wreak havoc on sensitive equipment andtest results. To meet demanding life science and analytical testingrequirements, Pall Corporation (NYSE: PLL), the global leader infiltration, separations and purification, announced that it isbringing its water purification expertise to the laboratory marketwith the introduction of the Pall Cascada(TM) Lab Water Systems. TheCascada point-of-use system provides optimum water quality to supportdiverse laboratory needs from the most critical, sensitiveapplications through general-purpose use.

"As the lab market becomes increasingly complex and demanding,customers need trustworthy providers that are deeply entrenched inwater purification," says Ken L. Harris, President Pall Life SciencesNew Technology. "Pall's entry into this marketplace combines more thana half century experience in the development of the most advancedwater purification technologies used by a host of industries worldwidewith our in-depth, extensive knowledge and understanding of thediverse application needs of the laboratory markets we serve."

The Cascada System enables laboratories to achieve the highestpurity water through a series of separation and purification steps ina single box on demand. Four polishing systems, with customizedconfigurations to meet a wide range of sensitive application requiresfor high quality ultrapure water, are available. A pretreatment systemis also available to protect and extend the life of the polishers,which is particularly important in cases where there is poor feedwaterquality.

Expanding Market with Unmet Needs

"The lab water market continues to expand and rapid technologicalgrowth in regions of the world, such as Asia and Latin America, stillhave many unmet needs. We are confident we will be one of the leadingproviders of point-of-use laboratory water systems in the nearfuture," says Mr. Harris.

The global laboratory water systems and consumables market isestimated at $250 million dollars, growing at a rate of about 8percent annually.

"Pall selected the best available technology for our new system tomonitor and protect the quality of the output water at the least costof ownership for academic, clinical, biopharmaceutical andpharmaceutical research laboratories," Mr. Harris adds. "The newCascada system is merely the tip of the iceberg for Pall in thismarketplace."

The Company plans to extend its dominant position in waterpurification by utilizing its proprietary technologies to continue torefine systems and lead in the growing, changing and ever moredemanding laboratory water market.

About Pall Corporation

Pall Corporation is the global leader in the rapidly growing fieldof filtration, separations and purification. Pall's business isorganized around two broad markets: Life Sciences and Industrial. TheCompany provides leading-edge products to meet the demanding needs ofcustomers in biotechnology, pharmaceutical, transfusion medicine,semiconductors, water purification, aerospace and broad industrialmarkets. Total revenues are $1.8 billion. The Company headquarters arein East Hills, New York with extensive operations throughout theworld. Visit Pall at

Forward Looking Statement

This release contains "forward-looking statements" as defined inthe Private Securities Litigation Reform Act of 1995. These statementsare based on current Company expectations and are subject to risks anduncertainties which could cause actual results to differ materially.Such risks and uncertainties include, but are not limited to:fluctuations in foreign currency exchange rates; regulatory approvaland market acceptance of new technologies; changes in product mix andproduct pricing and in interest rates and cost of raw materials; theCompany's success in enforcing its patents and protecting itsproprietary products and manufacturing techniques and its ability toachieve the savings anticipated from its cost reduction initiatives;global and regional economic conditions and legislative, regulatoryand political developments; and domestic and international competitionin the Company's global markets. Additional information regardingthese and other factors is available on the Web at and isincluded in the Company's reports filed with the U.S. Securities andExchange Commission. Copies of such reports can be obtained, withoutcharge, at

Management uses certain non-GAAP measurements to assess Pall'scurrent and future financial performance. The non-GAAP measurements donot replace the presentation of Pall's GAAP financial results. Thesemeasurements provide supplemental information to assist management inanalyzing Pall's financial position and results of operations. Pallhas chosen to provide this information to facilitate meaningfulcomparisons of past, present and future operating results and as ameans to emphasize the results of ongoing operations.

Editors Note:
Product photos and additional information can be found
CONTACT: Pall Corporation
Patricia Iannucci, 516- 801-9100
Source: Business Wire Press Release

Latest Press Release

Menarini: Elcin Barker Ergun Group CEO

"Elcin Barker Ergun is the ideal addition to the Menarini team, in order to continue the agenda of growth in geography and therapeutic areas," commented Eric Cornut, Chairman of Menarini. Elcin Barker Ergun: "Menarini is a company admired on a global...

Strekin AG Announces Completion of Patient Recruitment in the RESTORE Phase 3 Clinical Study of STR001

Strekin AG (, a biopharmaceutical company focused on treatments for hearing loss, announced today that it has successfully completed patient recruitment in the RESTORE study, an international, randomized, placebo-controlled, Phase 3...

Merck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations

- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with...

Updated Results for Investigational Therapy Tepotinib Presented at WCLC 2019

- Results include progression-free survival and overall survival data from Phase Ib/II INSIGHT study - Phase II INSIGHT 2 study now open for enrollment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal...

Newly Published ROSacea COnsensus (ROSCO) Expert Recommendations Encourage Dermatologists to Upweight Burden-related Discussions, Aim For #Complete Clearance# of Symptoms and Consider Combination Therapy For Severe Patients

Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Published online in the...

Related Topics